Tailoring tyrosine kinase inhibitors to fit the lung cancer genome

Related Experiment Video

Updated: Jun 3, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Brendan D Looyenga1, Irene Cherni, Jeffrey P Mackeigan

  • 1Van Andel Research Institute, Systems Biology, Grand Rapids, MI, USA.

Translational Oncology
|April 5, 2011
PubMed

Insights

Tyrosine kinase inhibitors (TKIs) are effective cancer drugs, but resistance emerges in non-small cell lung cancer (NSCLC). New therapies must target multiple pathways to overcome genetic heterogeneity and improve treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Tyrosine kinase inhibitors (TKIs) have been utilized as targeted cancer therapeutics for approximately ten years.
  • Genetic profiling of non-small cell lung carcinoma (NSCLC) has identified numerous tyrosine kinases as potential therapeutic targets.
  • TKIs demonstrate significant efficacy in treating specific malignancies with identifiable genetic mutations.

Purpose of the Study:

  • To review the effectiveness of TKIs in cancer treatment.
  • To discuss the challenges posed by genetic heterogeneity and pathway redundancy in advanced NSCLC.
  • To highlight the emergence of drug resistance and the need for advanced therapeutic strategies.

Main Methods:

  • Review of existing literature on TKIs in cancer therapy.
  • Analysis of genetic landscapes in NSCLC.
  • Examination of resistance mechanisms to TKIs like gefitinib and erlotinib.

Main Results:

  • TKIs are effective against cancers with specific genetic lesions.
  • Advanced NSCLC exhibits genetic heterogeneity and pathway redundancy, limiting single-agent therapy.
  • Drug resistance to TKIs is a significant clinical challenge.

Conclusions:

  • Targeted therapies using TKIs have revolutionized cancer treatment for certain cancers.
  • The complexity of advanced NSCLC necessitates multi-targeted therapeutic approaches.
  • Future cancer treatment paradigms must address genetic diversity and resistance mechanisms for improved efficacy.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.